RBRC09802 C (3-6 months) SPTLCはスフィンゴ脂質生合成、初発酵素であり細胞の生存に必須である。全身ノックアウトしたホモマウスは胎生初期に死ぬ。本マウスは組織特異的なノックアウトが可能であり、スフィンゴ脂質の研究に有用である。 B6;129(FVB)-Sptlc2<tm1.1Yhir> B6;129(FVB)-Sptlc2<tm1.1Yhir> 理研と阪大との共同研究で樹立した。Cre-を選抜し、fl/flの作出を行い、胚保存を実施した。 Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> SPTLC2のコンディショナルKO Sptlc2(serine palmitoyltransferase, long chain base subunit 2)floxed mice. Homozygous null mutants are embryonically lethal. Developed by Yoshio Hirabayashi, RIKEN Brain Science Institute in collaboration with Osaka University. R1 ES cell line [(129X1/SvJ x 129S1/Sv)F1] was used. Exon 3 was replaced with a fragment loxP-neo-loxP-Exon3-loxP. Neo fragment was removed by crossing with an EIIa-Cre mouse strain. R1 [(129X1/SvJ x 129S1/Sv)F1-Kitl<+>] 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Exp. Anim., 58, 515-524 (2009).<br>学術機関の学術研究に限る。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。 C(3〜6か月) true Phage P1 loxP sites, mouse Sptlc2 genomic DNA <a href='https://brc.riken.jp/mus/pcr09802'>Genotyping protocol -PCR-</a> In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Exp. Anim., 58, 515-524 (2009).The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. <A HREF="https://mus.brc.riken.jp/ja/mouse_of_month/jun_2017_mm" target="_blank">Mouse of the Month Jun 2017</A>